IP Library Granted Patent US 8,071,755
Granted Patent B2
US 8,071,755 · App. 12/098,196 · Granted Dec 6, 2011

Nucleotide analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,755
App. No.
12/098,196
Granted
Dec 6, 2011
Kind
B2
Abstract

The invention provides for nucleotide analogs and methods of using the same, e.g., for sequencing nucleic acids.

Claims (16)

1. A method for sequencing a nucleic acid, the method comprising the steps of:

exposing a nucleic acid duplex comprising a template portion and a primer portion to a nucleotide analog comprising an inhibitor that is charged or capable of becoming charged, wherein the inhibitor is attached to the analog via a cleavable linker, and a polymerase, under conditions that permit template-dependent incorporation of the analog into the primer;

detecting incorporation of the analog;

removing or neutralizing the inhibitor; and

repeating the exposing, detecting, and removing steps at least once, thereby to determine the sequence of the template.

2. The method of claim 1 , wherein the template portion and/or the primer portion is directly or indirectly anchored to a support.

3. The method of claim 1 , wherein the detecting step comprises detecting individual analogs.

4. The method of claim 1 further comprising the step of removing unincorporated analog.

5. The method of claim 1 , wherein the inhibitor is selected from the group consisting of one or more carboxylic acid, one or more phosphate, one or more amino acid, one or more peptide, one or more sulfate, one or more caproic acid, and any combination thereof.

6. The method of claim 5 , wherein the amino acid is a negatively charged amino acid.

7. The method of claim 6 , wherein the amino acid is selected from the group consisting of aspartic acid, glutamic acid, histidine, lysine, and arginine.

8. The method of claim 5 , wherein the peptide is from about 2 to about 10 amino acids in length.

9. The method of claim 1 , wherein the inhibitor comprises multiple charged groups.

10. The method of claim 1 , wherein the inhibitor is negatively charged.

11. The method of claim 1 , wherein the inhibitor is positively charged.

12. The method of claim 1 , wherein the inhibitor does not cause steric inhibition of the polymerase.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2013
From: HELICOS BIOSCIENCES CORPORATION
To: FLUIDIGM CORPORATION
Reel/Frame 030714/0546 →
LICENSE Recorded Jun 28, 2013
From: FLUIDIGM CORPORATION
To: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Reel/Frame 030714/0598 →
LICENSE Recorded Jun 28, 2013
From: FLUIDIGM CORPORATION
To: SEQLL, LLC
Reel/Frame 030714/0633 →
LICENSE Recorded Jun 28, 2013
From: FLUIDIGM CORPORATION
To: COMPLETE GENOMICS, INC.
Reel/Frame 030714/0686 →
LICENSE Recorded Jun 28, 2013
From: FLUIDIGM CORPORATION
To: ILLUMINA, INC.
Reel/Frame 030714/0783 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2012
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: HELICOS BIOSCIENCES CORPORATION
Reel/Frame 027549/0565 →
SECURITY AGREEMENT Recorded Nov 22, 2010
From: HELICOS BIOSCIENCES CORPORATION
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 025388/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2009
From: EFCAVITCH, J. WILLIAM; SIDDIQI, SUHAIB; BUZBY, PHILIP R.; MITCHELL, JUDITH; KRZYMANSKA-OLEJNIK, EDYTA; MARAPPAN, SUBRAMANIAN; BAI, XIAOPENG; ROY, ATANU; JAROSZ, MIRNA; BOWERS, JAYSON
To: HELICOS BIOSCIENCES CORPORATION
Reel/Frame 022800/0127 →